Yen Wen Yu
Patrimonio netto: 4 M $ in data 30/09/2026
Patrimonio netto: 4 M $ in data 30/09/2026
Mr. Yen Wen Yu is a Chief Operating Officer at Disc Medicine, Inc. Mr. Yu was previously employed as a Vice President-Finance & Operations by Qpex Biopharma, Inc. and a VP-Strategic Planning & Corporate Development by The Medicines Co. He received his undergraduate degree from Harvard College and an MBA from The Wharton School of the University of Pennsylvania.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
DISC MEDICINE, INC. 0,14% | 25/08/2026 | 54.324 ( 0,14% ) | 4 M $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| DISC MEDICINE, INC. | Direttore operativo | 07/02/2024 |
| Società | Posizione | Fine |
|---|---|---|
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Fondatore | 01/07/2020 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01/07/2018 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale